Cell and Gene Therapy 19/02/2018 Part Four: Cryopreservation This report provides a comprehensive guide to successfully investing in advanced therapies. It also outlines across six chapters each of the...
Cell and Gene Therapy 19/02/2018 Part Three: Transportation This five-part supply chain case study series continues with one of the transportation
Cell and Gene Therapy 19/02/2018 Part Two: Registration and Workflow Management The second step in the supply chain case study series is registration and workflow management
Cell and Gene Therapy 19/02/2018 Part One: Supply Chain Planning This five-part supply chain case study series begins with one of the most important factors in the success of your supply chain. Planning
Cell and Gene Therapy 15/02/2018 Viral Safety for ATMPS - Part One Pathogen safety is a crucial but sometimes overlooked aspect of the development of advanced therapy medicinal products
Cell and Gene Therapy 01/02/2018 Video: Advanced Therapies 2025 Industry leaders discuss the past, present and future of advanced therapies in this inspiring video...
Cell and Gene Therapy 31/01/2018 Winning Friends and Influencing Logistics in the Cell and Gene... Dr Alina Depkat is the customer relations manager at time:matters, a subsidiary of Lufthansa, the largest airline in Europe. She is leading...
Cell and Gene Therapy 23/01/2018 Top 15 Cell and Gene Therapy Biotechs to Watch in 2018 We're keeping tabs on the innovators and disruptors for you
Cell and Gene Therapy 22/01/2018 Regenerative Medicine Contract Manufacturing Organisations in Japan A summary of all of the regenerative medicine CMOs in Japan is presented in this infographic
Cell and Gene Therapy 22/01/2018 Cell and Gene Therapy Manufacturing Capacities in Europe 2017 Without capacity; manufacturing expertise; innovation and partnerships, advanced therapies cannot be commercialised nor delivered to patients ...
Cell and Gene Therapy 22/01/2018 Understanding the layers of complexity and working towards full... One of the main barriers to commercial viability for ATMPs is the supply chain, which contributes significantly to the overall cost of goods ...
Cell and Gene Therapy 18/01/2018 GMP Cell and Gene Therapy Manufacturing in the UK: Facilities,... The cell and gene therapy catapult review of MHRA licensed GMP manufacturing facilities in the UK provides an insightful picture of the capability...
Cell and Gene Therapy 11/01/2018 CRO Selection for Advanced Therapies How do you find the perfect CRO?
Cell and Gene Therapy 08/03/2017 Video: The Impact of Brexit on the British Advanced Therapeutic... Matthew Durdy, Chief Business Officer at Cell & Gene Therapy Catapult, gives his perspective on the impact of Brexit on the UK's advanced...
Cell and Gene Therapy 08/03/2017 Interview: Understanding development processes to ensure product... DR Felicia Rosenthal, CEO, Cellgenix discusses raw material for cell and tissue-based products, GMP manufacturing considerations and scale-up...
